Post Photo

06-23-2021

Bold Therapeutics Collaborates with Dr. Stephen Barr at Western University to Study BOLD-100 In COVID-19 Variants

Bold Therapeutics is pleased to be collaborating with Dr. Stephen Barr at Western University to study BOLD-100 in the COVID-19 variants of concern.
Post Photo

04-09-2021

BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting

Dr. Van Schaeybroeck will present research supporting BOLD-100 as a potential anti-resistance therapy for BRAF-mutant colorectal cancer at AACR annual meeting.

Post Photo

01-06-2021

Bold Therapeutics Collaborators at University of Vienna Published Study Detailing the Binding Partners and Mechanism of Action of BOLD-100

Bold Therapeutics collaborators at University of Vienna published a study detailing the binding partners and mechanism of action of BOLD-100.
Post Photo

09-17-2020

BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

Georgetown University has recently published a new manuscript showing that Bold Therapeutics� BOLD-100 has anti-cancer potential in breast cancer.
Post Photo

07-15-2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).
View All